Mr. Emili Torrell email@example.com Products/Services Oryzon, www.oryzon.com, HQ in Barcelona, Spain, is listed on MADX and a leader in the development of epigenetic-based therapies. Oryzon has delivered so far two LSD1i programs in the clinic: In oncology, ORY-1001, a selective LSD1i. It has finalized a Phase I/IIA in AML and a Phase I in SCLC. Phase IIA trials are in preparation. In CNS, ORY-2001, a dual LSD1-MAOBi. A Phase IIA in RR and SP forms of MS is ongoing and a Phase IIA in AD is in preparation.